Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations

Documenti analoghi

• Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
  di: Wen, Miaomiao, et al.
  Pubblicazione: (2018)
• Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
  di: Chen, Dan, et al.
  Pubblicazione: (2016)
• Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
  di: Yan, Han, et al.
  Pubblicazione: (2015)
• Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation
  di: Zhou, Shaozhang, et al.
  Pubblicazione: (2019)
• Efficacy and safety of bevacizumab combined with EGFR‐TKIs in advanced non‐small cell lung cancer: A meta‐analysis
  di: Yifan Yang, et al.
  Pubblicazione: (2022-01-01)